相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung Cancer
Nikki de Rouw et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis
Nikki de Rouw et al.
CLINICAL PHARMACOKINETICS (2021)
Toxicity of pemetrexed during renal impairment explained-Implications for safe treatment
Rene J. Boosman et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Simple and Rapid Quantification of the Multi-Enzyme Targeting Antifolate Pemetrexed in Human Plasma
Erik van den Hombergh et al.
THERAPEUTIC DRUG MONITORING (2020)
A limited sampling schedule to estimate individual pharmacokinetics of pemetrexed in patients with varying renal functions
Nikki de Rouw et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: A prospective cohort study
S. Visser et al.
EUROPEAN JOURNAL OF CANCER (2019)
Updates on the pathogenesis of advanced lung cancer-induced cachexia
Ruifang Zhu et al.
THORACIC CANCER (2019)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
Effect of renal function on pemetrexed-induced haematotoxicity
Yosuke Ando et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
N. Girard et al.
ANNALS OF ONCOLOGY (2015)
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
P. Baas et al.
ANNALS OF ONCOLOGY (2015)
Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer
Chung-Yu Chen et al.
CLINICAL LUNG CANCER (2015)
Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer
Madoka Kimura et al.
SUPPORTIVE CARE IN CANCER (2015)
Safety, Resource Use, and Quality of Life in PARAMOUNT A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
Cesare Gridelli et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study
Chandra P. Belani et al.
LANCET ONCOLOGY (2012)
A New Equation to Estimate Glomerular Filtration Rate
Andrew S. Levey et al.
ANNALS OF INTERNAL MEDICINE (2009)
Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients
JE Latz et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy
JE Latz et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function
AC Mita et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
分享论文
